Bacteriophage therapeutics: FDA clears first clinical study for PhageBank for the treatment of multi-drug resistant bacteria

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, announced recently that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of PhageBanka, a personalized bacteriophage therapeutic for the treatment ["]

The post Bacteriophage therapeutics: FDA clears first clinical study for PhageBank for the treatment of multi-drug resistant bacteria appeared first on Outbreak News Today.